Annual FCF
$50.52 M
+$22.63 M+81.11%
31 December 2022
Summary:
Eagle Pharmaceuticals annual free cash flow is currently $50.52 million, with the most recent change of +$22.63 million (+81.11%) on 31 December 2022. During the last 3 years, it has risen by +$1.77 million (+3.64%). EGRX annual FCF is now -8.49% below its all-time high of $55.21 million, reached on 31 December 2019.EGRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$132.00 K
+$33.44 M+99.61%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly free cash flow is currently -$132.00 thousand, with the most recent change of +$33.44 million (+99.61%) on 30 June 2023. EGRX quarterly FCF is now -100.31% below its all-time high of $42.99 million, reached on 30 June 2022.EGRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$9.39 M
-$43.12 M-127.84%
30 June 2023
Summary:
Eagle Pharmaceuticals TTM free cash flow is currently -$9.39 million, with the most recent change of -$43.12 million (-127.84%) on 30 June 2023. EGRX TTM FCF is now -109.73% below its all-time high of $96.57 million, reached on 30 September 2019.EGRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +3.6% | -112.4% | -123.8% |
| 5 y5 years | -3.3% | -101.3% | -109.7% |
EGRX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +81.1% | -100.3% | +99.6% | -118.6% | at low |
| 5 y | 5 years | -8.5% | +81.1% | -100.3% | +99.6% | -109.7% | at low |
| alltime | all time | -8.5% | +424.3% | -100.3% | +99.6% | -109.7% | +73.2% |
Eagle Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$132.00 K(-99.6%) | -$9.39 M(-127.8%) |
| Mar 2023 | - | -$33.57 M(-189.4%) | $33.73 M(-33.2%) |
| Dec 2022 | $50.52 M(+81.1%) | $37.55 M(-383.7%) | $50.52 M(+140.5%) |
| Sept 2022 | - | -$13.24 M(-130.8%) | $21.01 M(-40.5%) |
| June 2022 | - | $42.99 M(-356.2%) | $35.31 M(+3351.3%) |
| Mar 2022 | - | -$16.78 M(-308.9%) | $1.02 M(-96.3%) |
| Dec 2021 | $27.90 M(-42.8%) | $8.03 M(+656.3%) | $27.90 M(-29.3%) |
| Sept 2021 | - | $1.06 M(-87.8%) | $39.45 M(-10.0%) |
| June 2021 | - | $8.71 M(-13.7%) | $43.82 M(-22.0%) |
| Mar 2021 | - | $10.09 M(-48.5%) | $56.16 M(+15.2%) |
| Dec 2020 | $48.75 M(-11.7%) | $19.59 M(+261.0%) | $48.75 M(+88.7%) |
| Sept 2020 | - | $5.43 M(-74.2%) | $25.83 M(-15.9%) |
| June 2020 | - | $21.05 M(+683.6%) | $30.71 M(-3.7%) |
| Mar 2020 | - | $2.69 M(-180.6%) | $31.89 M(-42.2%) |
| Dec 2019 | $55.21 M(+5.7%) | -$3.33 M(-132.3%) | $55.21 M(-42.8%) |
| Sept 2019 | - | $10.31 M(-53.6%) | $96.57 M(+7.4%) |
| June 2019 | - | $22.23 M(-14.5%) | $89.91 M(+22.6%) |
| Mar 2019 | - | $26.00 M(-31.6%) | $73.35 M(+40.4%) |
| Dec 2018 | $52.25 M(-2.8%) | $38.03 M(+940.4%) | $52.25 M(+39.7%) |
| Sept 2018 | - | $3.65 M(-35.5%) | $37.41 M(-6.6%) |
| June 2018 | - | $5.67 M(+15.6%) | $40.07 M(-44.1%) |
| Mar 2018 | - | $4.90 M(-78.9%) | $71.75 M(+33.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $53.73 M(+65.2%) | $23.19 M(+267.3%) | $53.73 M(-16.7%) |
| Sept 2017 | - | $6.31 M(-83.1%) | $64.49 M(+12.8%) |
| June 2017 | - | $37.34 M(-384.8%) | $57.16 M(+234.3%) |
| Mar 2017 | - | -$13.11 M(-138.6%) | $17.10 M(-47.4%) |
| Dec 2016 | $32.52 M(-380.3%) | $33.95 M(-3457.9%) | $32.52 M(-273.8%) |
| Sept 2016 | - | -$1.01 M(-62.9%) | -$18.71 M(-26.3%) |
| June 2016 | - | -$2.72 M(-218.2%) | -$25.41 M(-27.6%) |
| Mar 2016 | - | $2.30 M(-113.3%) | -$35.09 M(+202.5%) |
| Dec 2015 | -$11.60 M(-16.5%) | -$17.28 M(+124.3%) | -$11.60 M(+426.5%) |
| Sept 2015 | - | -$7.71 M(-37.9%) | -$2.20 M(+35.0%) |
| June 2015 | - | -$12.40 M(-148.1%) | -$1.63 M(-126.8%) |
| Mar 2015 | - | $25.79 M(-427.1%) | $6.10 M(-128.0%) |
| Dec 2014 | - | -$7.89 M(+10.5%) | -$21.79 M(+56.9%) |
| Sept 2014 | -$13.89 M(+134.6%) | -$7.14 M(+52.8%) | -$13.89 M(+96.2%) |
| June 2014 | - | -$4.67 M(+122.5%) | -$7.08 M(+36.9%) |
| Mar 2014 | - | -$2.10 M(<-9900.0%) | -$5.17 M(+26.3%) |
| Dec 2013 | - | $16.00 K(-104.9%) | -$4.10 M(-30.8%) |
| Sept 2013 | -$5.92 M(-62.0%) | -$325.70 K(-88.2%) | -$5.92 M(+5.8%) |
| June 2013 | - | -$2.76 M(+170.3%) | -$5.59 M(+97.6%) |
| Mar 2013 | - | -$1.02 M(-43.5%) | -$2.83 M(+56.5%) |
| Dec 2012 | - | -$1.81 M | -$1.81 M |
| Sept 2012 | -$15.58 M | - | - |
FAQ
- What is Eagle Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual free cash flow?
The current annual FCF of EGRX is $50.52 M
What is the all time high annual FCF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual free cash flow is $55.21 M
What is Eagle Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of EGRX is -$132.00 K
What is the all time high quarterly FCF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly free cash flow is $42.99 M
What is Eagle Pharmaceuticals TTM free cash flow?
The current TTM FCF of EGRX is -$9.39 M
What is the all time high TTM FCF for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM free cash flow is $96.57 M